Enzyme Kinetics

Overview

Enzyme kinetics is the study of the rates at which enzyme-catalyzed reactions occur and the factors that influence them. Enzymes are biological catalysts — mostly proteins — that accelerate chemical reactions by factors of millions to trillions without being consumed in the process. Understanding enzyme kinetics is essential in the peptide field because enzymes called peptidases (proteases) are the primary agents responsible for peptide degradation in vivo, and much of peptide drug design revolves around resisting or exploiting enzymatic activity.

The kinetic parameters of an enzyme describe how efficiently it converts substrates to products, how susceptible it is to inhibition, and how its activity is regulated. These parameters directly influence the half-life, bioavailability, and pharmacokinetics of peptide therapeutics.

The Michaelis-Menten Model

The foundational model of enzyme kinetics, developed by Leonor Michaelis and Maud Menten in 1913, describes the relationship between substrate concentration and reaction rate for a simple one-substrate enzyme:

E + S <-> ES -> E + P

Where E is the enzyme, S is the substrate, ES is the enzyme-substrate complex, and P is the product. The model yields the Michaelis-Menten equation:

v = Vmax [S] / (Km + [S])

Key Parameters

• Vmax (maximum velocity) — The maximum reaction rate when all enzyme molecules are saturated with substrate. Vmax depends on enzyme concentration and the catalytic rate constant (kcat).
• Km (Michaelis constant) — The substrate concentration at which the reaction rate is half of Vmax. Km is often interpreted as an approximate measure of the enzyme's affinity for its substrate: a low Km indicates high affinity (the enzyme reaches half-maximal velocity at low substrate concentration), while a high Km indicates low affinity.
• kcat (turnover number) — The number of substrate molecules converted to product per enzyme molecule per unit time at saturation. For fast enzymes, kcat can exceed 10,000 per second.
• kcat/Km (catalytic efficiency) — The ratio of kcat to Km, measuring overall enzyme efficiency. The theoretical upper limit is set by the rate of diffusion-limited encounter between enzyme and substrate (approximately 10^8 to 10^9 M^-1 s^-1).

Types of Enzyme Inhibition

Enzyme inhibitors are molecules that decrease enzyme activity. Inhibitor design is a major strategy in peptide pharmacology — many therapeutic peptides are either protease inhibitors themselves or have been modified to resist protease degradation.

Competitive Inhibition

The inhibitor binds the active site, competing directly with the substrate. Competitive inhibitors increase the apparent Km (the enzyme needs more substrate to reach half-Vmax) but do not affect Vmax (at sufficiently high substrate concentrations, the substrate outcompetes the inhibitor). Many protease inhibitors are competitive — they resemble the substrate but are not cleaved.

Non-Competitive Inhibition

The inhibitor binds an allosteric site (not the active site) and reduces enzyme activity regardless of substrate concentration. Non-competitive inhibitors decrease Vmax without affecting Km. See Allosteric Modulation.

Uncompetitive Inhibition

The inhibitor binds only to the enzyme-substrate complex, not to the free enzyme. This decreases both Vmax and apparent Km.

Mixed Inhibition

The inhibitor can bind both the free enzyme and the enzyme-substrate complex, with different affinities. This alters both Vmax and apparent Km.

Irreversible Inhibition

The inhibitor forms a covalent bond with the enzyme, permanently inactivating it. Recovery of enzyme activity requires new enzyme synthesis. Some therapeutic strategies exploit irreversible inhibition for sustained effects.

Peptidases: Enzymes That Degrade Peptides

Peptidases (proteases) are the enzymes most directly relevant to the peptide field. They cleave peptide bonds and are classified by their catalytic mechanism:

• Serine proteases — Use a serine residue in the active site (trypsin, chymotrypsin, elastase, thrombin). Many coagulation-cascade enzymes are serine proteases.
• Cysteine proteases — Use a cysteine thiol (caspases, cathepsins). Caspases are key effectors of apoptosis.
• Aspartic proteases — Use aspartate residues (pepsin, renin). Renin is a target in the renin-angiotensin system.
• Metalloproteases — Require a metal ion, typically zinc (matrix metalloproteinases, ACE, neprilysin). Neprilysin degrades natriuretic peptides, substance P, and bradykinin.
• Threonine proteases — The proteasome uses threonine residues to degrade ubiquitinated proteins.

Exopeptidases vs. Endopeptidases

Exopeptidases cleave amino acids from the termini of peptide chains (aminopeptidases from the N-terminus, carboxypeptidases from the C-terminus). Endopeptidases cleave internal peptide bonds. The susceptibility of a peptide to each type influences strategies for improving stability — for example, N-terminal acetylation and C-terminal amidation protect against exopeptidases.

Relevance to Peptide Drug Design

Understanding enzyme kinetics directly informs the design of more stable and effective peptide therapeutics:

• DPP-IV resistance — The enzyme dipeptidyl peptidase-IV rapidly cleaves native GLP-1 at its N-terminus. Semaglutide, liraglutide, and dulaglutide are all engineered to resist DPP-IV cleavage, dramatically extending their half-lives.
• NEP resistance — Neprilysin degrades many vasoactive peptides. Nesiritide (recombinant BNP) has a short half-life partly due to neprilysin activity; the drug sacubitril inhibits neprilysin to increase endogenous natriuretic peptide levels.
• ACE inhibition — Angiotensin-converting enzyme converts angiotensin I to angiotensin II. ACE inhibitors are among the most widely prescribed cardiovascular drugs.
• First-pass metabolism — Oral peptides must survive gastrointestinal peptidases and hepatic enzymes. The challenge of oral peptide delivery is fundamentally a problem of enzyme kinetics.

See Also

• Protease — The enzymes that degrade peptides
• Half-Life — How enzyme degradation determines peptide duration
• Pharmacokinetics — The study of drug absorption, distribution, metabolism, and elimination
• First-Pass Metabolism — Enzymatic degradation during oral absorption
• Peptide Degradation — Mechanisms of peptide breakdown in vivo